Why Psychedelic Delivery Mechanisms Matter
Ryan Allway
October 2nd, 2020
App, Exclusive, News, Psychedelics, Top News
The psychedelics industry is poised to become a nearly $7 billion market by 2027, according to Data Bridge Market Research, driven by the potential to revolutionize the treatment of mental health disorders. While investors have many options in the space, the best positioned companies are combining delivery mechanisms with novel compounds to create IP strategies.
Let’s take a look at why delivery mechanisms matter and how Cybin Corp. is leveraging sublingual delivery to revolutionize psychedelic therapies.
What Are Delivery Mechanisms?
Most pharmaceuticals come from natural sources—and the same is true for both cannabis and psychedelics. Of course, the final product that people pick up from the pharmacy is typically pill, capsule, spray, suppository or other delivery mechanism.
Delivery mechanisms play an important role in ensuring the bioavailability and optimal delivery of pharmaceutical compounds. For instance, extended release tablets slowly release an active pharmaceutical ingredient, or API, over time rather than all at once. These capabilities can be transformative for chronic pain relief therapies by making a once-a-day option.
Aside from convenience and performance, delivery mechanisms may be required for any efficacy. The most common problem experienced by some pharmaceuticals is first-pass metabolism in the liver. While it’s possible to simply increase the dosage, there are many instances where high doses become toxic, making a delivery mechanism essential.
Benefits of Delivery Mechanisms
The most obvious benefit of a delivery mechanism is that it improves the performance of a pharmaceutical compound or makes it safe to use. But aside from these benefits, there are several other reasons to develop innovative delivery mechanisms.
Delivery mechanisms are a common way to patent natural compounds or extend expiring patents. While patients and consumers can still access cheap natural compounds or legacy products, these delivery mechanisms typically improve the efficacy of the compound or offer other benefits that may encourage commercial adoption.
The development of delivery mechanisms themselves also represents unique intellectual property. Investors in these companies benefit from both a potentially efficacious and unique delivery, as well as the ability to leverage the same delivery technology across a wide range of different compounds—or even the ability to license it to others.
Cybin’s Psychedelic Approach
Cybin Corp. is focused on psychedelic drug development, unique delivery mechanisms, improved novel compounds and protocols that target psychiatric and neurological conditions.
Watch Cybin CEO Doug Drysdale discuss the innovative delivery mechanism:
Click here to learn more about investing in Cybin and receive corporate updates
The company’s wholly owned subsidiary, Serenity Life Sciences, has developed a fast-acting sublingual delivery strip technology that provides both improved bioavailability and greater convenience for patients. In particular, sublingual delivery offers fast access to the bloodstream and bypasses second-pass metabolism in the liver.
The unique delivery mechanism is being used in a Phase II randomized, parallel group, bioequivalence study of psilocybin for the treatment of Major Depressive Disorder. If successful, the company could become one of the first life science companies to launch a fully approved psilocybin product targeting depression.
Watch CEO Doug Drysdale outline the company’s clinical trial strategy:
Click here to learn more about investing in Cybin and receive corporate updates
Looking Ahead
Cybin Corp. could become one of the first life sciences companies to commercialize psilocybin for the treatment of depression. With an innovative delivery mechanism, the company developed a patentable product with potentially significant advantages over other forms of psilocybin, creating an attractive commercial opportunity.
The company plans to go public through a reverse-takeover of Clarmin Explorations on the TSX Venture exchange. In connection with the going public transaction, the company plans to raise a minimum of $14 million and a maximum of $21 million to fund its ongoing research and development activities.
For more information, visit the company’s website or download the investor presentation.
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
Rob is the co-founding President of Pelorus Equity Group and has more than 18 years of experience in the real estate finance industry. Since the formation of Pelorus in 2010, he has raised more than $175,000,000 in secured real estate transactions. Rob’s primary role at Pelorus Equity Group is the development of strategic alliances with […]
BDS Analytics aims to drive the cannabis sector to thrive with well-informed decisions based on factual data. By capturing millions of transactions from dispensary point-of-sale systems we provide actionable insights based on accurate information enabling dispensaries, brands, and growers to sustain their success. Their vision is to be your indispensable source for cannabis industry data […]
Delta 9’s wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical marijuana pursuant to the ACMPR and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada . Delta 9’s shares trade on the TSX Venture Exchange under the symbol “NINE”.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
